Ginseng focus trial halted early – little to go on

NCT ID NCT07255755

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a single 200 mg dose of American Ginseng (Cereboost) could improve attention and brain function in healthy young adults aged 18-40. Participants completed cognitive tests and gave blood samples over 6 hours. However, the trial was terminated early and only enrolled 27 people, so no reliable conclusions can be drawn.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

American Ginseng extract (Cereboost)

What this could lead to

If it worked, this could suggest a natural supplement for short-term attention or focus in healthy people.

What could go wrong

The trial was terminated early with only 27 participants, so results are incomplete and unreliable. Any benefits would be small and temporary, not a treatment for any condition.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COGNITION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

attention deficit hyperactivity disorder, inattentive type cognitive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Quadram Insitute Clinical Research Facility

    Norwich, Norfolk, NR4 7UQ, United Kingdom

  • University of East Anglia

    Norwich, Norfolk, NR4 7UQ, United Kingdom